tirzepatide is semaglutide Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity Maintenance therapy on semaglutide or

The prevalence of HFpEF is rising, increasing from 33 to 39% between 2005 and 2010, with projections suggesting it will soon become the most common form of HF [5, 6]

When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.5), Adverse Reactions (6)]

The results may also shape how pharmaceutical companies approach future trials of weight-loss and diabetes drugs for brain diseases

10.1056/NEJMoa1307684 27

Physician-prescribed, lab-informed, and structured around what's actually happening in your metabolism